Articles On Cellmid (ASX:CDY)

The revenue result is an improvement on the prior TSV events in June 2019 as well as in December 2019.

A quick wrap of the key winners and losers on Monday, June 15. Data is taken after the market closes at 4pm EST. Stocks highlighted in yellow made market-moving announcements during the day. The ASX had a modest start but tumbled in the las...

There is a growing body of evidence that serology-based assays increase the accuracy and speed of diagnosis when combined with PCR methods and assessment of clinical symptoms.

Emerging scientific evidence has been consistent that using nucleotide and antibody tests together improves accuracy of diagnosis for COVID-19 patients.

Prior to joining Cellmid Dr Burg received his PhD from the University of New South Wales

Participating in small cap raises is proving lucrative for investors, with shares in 47 small caps that tapped equity markets in April currently trading higher than the price at which they raised cash. Stockhead counted at least 66 offers i...

Two COVID-19 antibody kits have failed post-market testing, raising more questions about the 20 point-of-care kits approved for sale in Australia. Four of the 20 point-of-care tests (PoCT) available in Australia have now failed independent...

Pre-revenue biotech and medtech companies are still not eligible for the Jobkeeper wage subsidy according to the ATO, a double whammy for a swathe of research-driven ASX businesses with large staff costs. The Jobkeeper program allows busine...

It’s still a relatively difficult market to raise capital in, particularly at the junior end, but there are some that have convinced investors to part with their hard earned cash. We run through just which small and micro caps successfully...

The company’s consumer health division, Advangen, develops, manufactures and markets innovative products for hair loss, thinning and hair ageing in Australia, Japan, the USA, Europe and Asia.

Cellmid has signed an agreement with Australia Applications (Wondfo’s Australian agent) for the supply of the tests in Australia.

Clinical trials are being shuttered in increasing numbers in Australia because of the risks posed by COVID-19, but two companies this morning say theirs are moving ahead at speed. Prescient Therapeutics (ASX:PTX) says its phase 1b study of...

Our summary of Cellmid Ltd's recent announcement What's happened? Cellmid Limited (ASX:CDY) has announced that a validation study has been completed for the Wondfo SARS-COV-2 test, which Cellmid had previously signed a supply agreement for...

The SPP is offered to shareholders who at the record date on April 6 had a registered address in Australia or New Zealand.

The Cellmid sponsored Wondfo SARS-CoV-2 kit is manufactured in a facility certified by the Australian Therapeutic Goods Administration (TGA).

The ASX says Cellmid CEO Maria Halasz spruiked its COVID-19 diagnostic test kit in social media before informing the market.

Cellmid, an Australian life sciences company with a consumer health business and biotech assets, has recently secured a supply agreement for a SARS-CoV-2 rapid diagnostic test.

In proof that biotechs will deliver market returns even during a pandemic, two companies this morning have issued clinical trial results and watched their share prices rocket. Pot stock Zelira Therapeutics (ASX:ZLD) has received the full re...

“We are excited to be able to contribute to Australia’s comprehensive effort to manage this pandemic,” said Cellmid CEO Maria Halasz.

Our summary of Cellmid Ltd's recent announcement What's happened? Cellmid Limited (ASX:CDY) has raised $6 million (before costs) via a share placement from institutional and sophisticated investors. What are the key highlights? The Placeme...

The market for COVID-19 diagnostic kits is much broader than just the health sector, as miners and other industries begin to compete for tests with governments. But where diagnostic tests normally require at minimum several months of patien...

The company is playing a role in Australia’s efforts to combat COVID-19 through an agreement to supply rapid diagnostic tests (RDT).

When the share market closed on Friday a little-known Australian life sciences company called Cellmid (ASX: CDY) was in a trading halt after selling at lows not seen since 2009. The loss-making group has been in the thick of a turnaround...

Cellmid Ltd. [ASX:CDY], an Australian based biotechnology company, went into a trading halt on 20 March 2020 after falling to a close share price the previous day of $0.09. The post Will Cellmid Bounce Back from Its Trading Halt? (ASX:CDY)...

“We are excited to be able to contribute to Australia’s comprehensive effort to manage this pandemic,” said Cellmid CEO Maria Halasz.

Stockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade. It’s a short, sharp update to help frame the trading day by showing the biggest movers in percentage terms. The market opens at 10am (easte...

“We are excited to be able to contribute to Australia’s comprehensive effort to manage this pandemic,” said Cellmid CEO Maria Halasz.

Our summary of Cellmid Ltd's recent announcement What's happened? Cellmid Ltd (ASX: CDY, “Cellmid”) have announced that it has entered into a supply agreement for a COVID-19 rapid diagnostic test with an authorized distributor of the manufa...

Life sciences company Cellmid (ASX: CDY) is set to come out of its self-imposed trading halt on Monday with news that it will commercialise a rapid test capable of detecting coronavirus (COVID-19) within 15 minutes. First developed in China...

Cellmid sells anti-aging products such as for hair growth and generated $3.66 million in revenue in the recent December half.

Stockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade. It’s a short, sharp update to help frame the trading day by showing the biggest movers in percentage terms. The market opens at 10am (easte...

What's happened? Cellmid Limited (ASX:CDY, "Cellmid") released its financial results for 1H FY2020. What are the key highlights? Consumer health revenue increased by 5.5% to $3.66 million (up from $3.49 million in H1 FY2019). Revenue was a...

The financial impact of the new distribution channels has started to show in the USA and in Australia, where sales were up 74% and 24% respectively.

Cellmid’s wholly owned subsidiary Advangen has a range of FGF5 inhibitor hair growth products which are sold in Australia, Japan, USA and China.

Life science company Cellmid (CDY) has received a notice of intention from the Chinese Patent Office for its evolis brand This is a key milestone for the company’s strategy of protecting and establishing evolis in China Evolis is Cellmid...

Resonance Health (ASX:RHT) has licensed its flagship liver iron concentration MRI service to another distributor in its biggest market, the US. 3DR has bought a non-exclusive licence to sell FerriSmart in the US. The stock was up 24 per cen...

Life sciences company Cellmid (ASX: CDY) has told the market it is tentatively expecting to receive a patent from the Chinese Patent Office for its évolis brand in the very near future. Earlier today, Cellmid said that Chinese authorities h...

What's happened? Cellmid Limited (ASX:CDY, 'Cellmid') have released their Quarterly Activities Report for Q2 FY2020. What are the top 10 key highlights? Consumer health sales in Q2 FY2020 increased 19% to $2.45M (2Q FY2019: $2.06M) with st...

Asia is rising as a healthcare spender, matching incomes and the long-feared elderly population boom. The region is a major part of a surge in health spending that is expected over the next few years, as rising lifestyle illnesses and ages...

Cellmid (CDY) has received notice of allowance for an improved antibody patent from the United States Patent and Trademark Office Key U.S. and European patents have now been granted for its midkine antibodies These patents secure protect...

The two new patents are important for partnering opportunities and as such represent commercial value for the life sciences company.

What's happened Cellmid Ltd ("Cellmid") has received notice of allowance for its Improved midkine antibody patent from the United States Patent and Trademark Office (USPTO). Further to this, the European Patent Office (EPO) has also now iss...

You don’t need a PhD to run a biotech, but sometimes it helps, as these companies deal in one of the most complicated mysteries still to be solved today: the human body. Biotech CEOs and chairs tend to be the cross-over scientists. However,...

Cellmid Ltd (ASX:CDY) is a life sciences company focused on developing solutions for conditions associated with aging

Other QVC TV shopping channels in USA, Germany and UK are expected to come online in 2020.

Through wholly-owned subsidiaries such as Lyramid, Kinera and Advangen, the company develops and markets innovative novel therapies as well as diagnostic tests for inflammatory and fibrotic diseases, cancer, ischemic diseases of the heart a...

The company recently entered into a trading agreement with API Services Australia Pty Ltd for the range of évolis® Professional anti-ageing haircare products to be sold in Priceline Pharmacies throughout Australia.

The Agreement Cellmid have entered into a national trading agreement with API Services Australia Pty Ltd (API) for the ranging of the Company’s évolis® Professional anti-aging hair care products in Priceline Pharmacies. As part of this trad...